SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001140361-12-028474
Filing Date
2012-06-04
Accepted
2012-06-04 13:44:27
Documents
1
Group Members
PLATINUM PARTNERS VALUE ARBITRAGE FUND LP

Document Format Files

Seq Description Document Type Size
1 PLATINUM-MONTAUR LIFE SCIENCES, LLC SC 13DA #2 4-2-2012 (NAVIDEA BIOPHARMACEUTIC formsc13da.htm SC 13D/A 135926
  Complete submission text file 0001140361-12-028474.txt   137630
Mailing Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017
Business Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Subject) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-43603 | Film No.: 12885497
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 152 WEST 57TH STREET 54TH FLOOR NEW YORK NY 10019
Business Address 152 WEST 57TH STREET 54TH FLOOR NEW YORK NY 10019 (212) 582-2222
Platinum-Montaur Life Sciences, LLC (Filed by) CIK: 0001404598 (see all company filings)

IRS No.: 260204840 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A